By Nicolas Hulscher, MPH The Biopharmaceutical Complex is preparing for the large-scale deployment of replicon (self-amplifying) mRNA injections. There are currently at least 33 candidates in development.
These products behave like a synthetic virus. The replicon mRNA is designed to encode not only the target antigen but also viral replicase, enabling the mRNA to replicate itself within the target cells. This replication machinery allows for an unknown period of toxic antigen production. Concerningly, none of the clinical trials have addressed the major concern of product shedding.
By Nicolas Hulscher, MPH
The Biopharmaceutical Complex is preparing for the large-scale deployment of replicon (self-amplifying) mRNA injections. There are currently at least 33 candidates in development.
https://open.substack.com/pub/petermcculloughmd/p/attack-of-the-replicons
These products behave like a synthetic virus. The replicon mRNA is designed to encode not only the target antigen but also viral replicase, enabling the mRNA to replicate itself within the target cells. This replication machinery allows for an unknown period of toxic antigen production. Concerningly, none of the clinical trials have addressed the major concern of product shedding.
作者：Nicolas Hulscher，MPH
生物製藥綜合體正在為複製子（自放大）mRNA注射的大規模部署做準備。 目前至少有33名候選人正在開發中。
這些產品的行為就像合成病毒。 複製子mRNA不僅用於編碼目標抗原，還用於編碼病毒複製酶，使mRNA能夠在目標細胞內複製自己。 這種複製機制允許在未知的有毒抗原生產期間。 令人擔憂的是，沒有一項臨床試驗能解決產品脫落的主要問題。